Lamy Patrick, Senior VP of Commercial Strategy at Akero Therapeutics ($AKRO), sold shares on the open market eleven times over the past year, totaling about $1.05 million. His most recent sale occurred on July 1, 2025. These AKRO insider sales rank 4,798th among 11,678 individuals in our database, where the average is roughly $8.6 million across about 6.4 transactions. Patrick made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec. 9, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | See Remarks | D | Stock Option (Right to Buy) | 11096 | $0.00 | 0.0000 | 82,316,179 | 100.00% | 0.01% |
| Dec. 9, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | See Remarks | D | Stock Option (Right to Buy) | 382 | $0.00 | 0.0000 | 82,316,179 | 100.00% | 0.00% |
| Dec. 9, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | See Remarks | D | Stock Option (Right to Buy) | 3421 | $0.00 | 0.0000 | 82,316,179 | 100.00% | 0.00% |
| Dec. 9, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | See Remarks | D | Common Stock | 26832 | $0.00 | 0.0000 | 82,316,179 | 100.00% | 0.03% |
| Dec. 9, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | See Remarks | D | Common Stock | 3059 | $0.00 | 0.0000 | 82,316,179 | 100.00% | 0.00% |
| Dec. 9, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | See Remarks | D | Stock Option (Right to Buy) | 64182 | $0.00 | 0.0000 | 82,316,179 | 100.00% | 0.08% |
| Dec. 9, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | See Remarks | D | Stock Option (Right to Buy) | 48679 | $0.00 | 0.0000 | 82,316,179 | 100.00% | 0.06% |
| Dec. 9, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | See Remarks | D | Stock Option (Right to Buy) | 84904 | $0.00 | 0.0000 | 82,316,179 | 100.00% | 0.10% |
| July 1, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | S | Common Stock | 2000 | $52.88 | 29,891.0000 | 79,620,128 | 6.27% | 0.00% |
| June 30, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | A | Common Stock | 193 | $23.87 | 31,891.0000 | 79,620,128 | 0.61% | 0.00% |
| June 16, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | S | Common Stock | 500 | $55.09 | 32,573.0000 | 79,620,128 | 1.51% | 0.00% |
| June 20, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | S | Common Stock | 875 | $54.59 | 31,698.0000 | 79,620,128 | 2.69% | 0.00% |
| June 16, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | M | Common Stock | 2000 | $19.87 | 34,573.0000 | 79,620,128 | 6.14% | 0.00% |
| June 16, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | S | Common Stock | 1500 | $53.82 | 33,073.0000 | 79,620,128 | 4.34% | 0.00% |
| June 16, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | M | Stock Option (Right to Buy) | 2000 | $0.00 | 64,182.0000 | 79,620,128 | 3.02% | 0.00% |
| June 10, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | S | Common Stock | 919 | $54.00 | 32,573.0000 | 79,620,128 | 2.74% | 0.00% |
| June 2, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | M | Stock Option (Right to Buy) | 4000 | $0.00 | 66,182.0000 | 79,620,128 | 5.70% | 0.01% |
| June 2, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | M | Common Stock | 4000 | $19.87 | 37,492.0000 | 79,620,128 | 11.94% | 0.01% |
| June 2, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | S | Common Stock | 600 | $49.40 | 36,892.0000 | 79,620,128 | 1.60% | 0.00% |
| June 2, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | S | Common Stock | 3300 | $50.46 | 33,592.0000 | 79,620,128 | 8.95% | 0.00% |
| June 2, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | S | Common Stock | 100 | $51.04 | 33,492.0000 | 79,620,128 | 0.30% | 0.00% |
| May 22, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | M | Stock Option (Right to Buy) | 4000 | $0.00 | 84,904.0000 | 79,620,128 | 4.50% | 0.01% |
| May 22, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | S | Common Stock | 4000 | $50.00 | 33,492.0000 | 79,620,128 | 10.67% | 0.01% |
| May 22, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | M | Common Stock | 4000 | $44.37 | 37,492.0000 | 79,620,128 | 11.94% | 0.01% |
| May 7, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | S | Common Stock | 3299 | $42.76 | 33,492.0000 | 79,620,128 | 8.97% | 0.00% |
| May 7, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | M | Stock Option (Right to Buy) | 8000 | $0.00 | 70,182.0000 | 79,620,128 | 10.23% | 0.01% |
| May 7, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | S | Common Stock | 4701 | $42.31 | 36,791.0000 | 79,620,128 | 11.33% | 0.01% |
| May 7, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | M | Common Stock | 8000 | $19.87 | 41,492.0000 | 79,620,128 | 23.89% | 0.01% |
| March 3, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | M | Stock Option (Right to Buy) | 1000 | $0.00 | 78,182.0000 | 79,620,128 | 1.26% | 0.00% |
| March 3, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | S | Common Stock | 1000 | $48.09 | 33,492.0000 | 79,620,128 | 2.90% | 0.00% |
| March 3, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | M | Common Stock | 1000 | $19.87 | 34,492.0000 | 79,620,128 | 2.99% | 0.00% |
| Jan. 27, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | M | Common Stock | 4000 | $19.87 | 38,492.0000 | 0 | 11.60% | 0.00% |
| Jan. 27, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | S | Common Stock | 5000 | $57.03 | 33,492.0000 | 0 | 12.99% | 0.00% |
| Jan. 27, 2025 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | M | Stock Option (Right to Buy) | 4000 | $0.00 | 79,182.0000 | 0 | 4.81% | 0.00% |
| Dec. 31, 2024 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | A | Common Stock | 234 | $19.69 | 34,492.0000 | 0 | 0.68% | 0.00% |
| Dec. 16, 2024 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | A | Stock Option (Right to Buy) | 52100 | $0.00 | 52,100.0000 | 0 | 9999.99% | 0.00% |
| Dec. 16, 2024 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | S | Common Stock | 1000 | $29.13 | 34,258.0000 | 0 | 2.84% | 0.00% |
| Dec. 16, 2024 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | A | Common Stock | 17400 | $0.00 | 35,258.0000 | 0 | 97.44% | 0.00% |
| Dec. 10, 2024 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | S | Common Stock | 925 | $30.79 | 17,858.0000 | 0 | 4.92% | 0.00% |
| June 28, 2024 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | A | Common Stock | 221 | $19.94 | 18,783.0000 | 0 | 1.19% | 0.00% |
| June 11, 2024 | Akero Therapeutics, Inc. | $AKRO | Lamy Patrick | Senior VP, Commercial Strategy | S | Common Stock | 569 | $22.64 | 18,562.0000 | 0 | 2.97% | 0.00% |